American International Group’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
– Sell
-50
Closed -$61K – 3232
2022
Q1
$61K Sell
50
-3
-6% -$4.08K ﹤0.01% 2781
2021
Q4
$134K Sell
53
-2
-4% -$12.2K ﹤0.01% 2592
2021
Q3
$1M Sell
55
-1
-2% -$15.9K 0.01% 1447
2021
Q2
$592K Buy
56
+10
+22% +$83.9K ﹤0.01% 1813
2021
Q1
$330K Hold
46
– – ﹤0.01% 2075
2020
Q4
$254K Sell
46
-1
-2% -$8.86K ﹤0.01% 2153
2020
Q3
$470K Sell
47
-1
-2% -$9.1K ﹤0.01% 1620
2020
Q2
$445K Buy
48
+14
+41% +$128K ﹤0.01% 1659
2020
Q1
$307K Sell
34
-2
-6% -$19.7K ﹤0.01% 1671
2019
Q4
$400K Buy
36
+27
+300% +$163K ﹤0.01% 1823
2019
Q3
$47K Hold
9
– – ﹤0.01% 2899
2019
Q2
$78K Buy
+9
New +$53.8K ﹤0.01% 2802

Other funds holding IRLA

American International Group's IRLA Position: Q2 2022 in Review

American International Group sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q2 2022, closing a stake of 50 shares — an estimated $61K sold.

American International Group first reported a position in IRLA in Q2 2019 and held it in 12 quarters. The position peaked at $1M in Q3 2021. 66 funds tracked by Wall St. Rank hold IRLA as of Q2 2022.

  • American International Group reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • American International Group sold 50 IRulya Therapeutics Inc. Common Stock shares in Q2 2022, an estimated $61K.
  • American International Group first reported a position in IRulya Therapeutics Inc. Common Stock in Q2 2019 and held it in 12 quarters.
  • American International Group's IRulya Therapeutics Inc. Common Stock position peaked at $1M in Q3 2021.
  • 66 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2022.

Based on American International Group's 13F filing for Q2 2022, filed 12 Aug 2022.